Shattuck Labs (Shattuck Labs (STTK)) shares are swinging around Wednesday after the clinical-stage biotech company announced the pricing of a public offering of its common stock. The offering is expected to bring in roughly $75 million before underwriting fees, which can sometimes spook investors due to dilution concerns.
The company priced the offering at $4.00 per share for 10,879,376 shares, along with pre-funded warrants at $3.9999 each. The deal is expected to close on June 11, 2026, subject to standard conditions. Shattuck Labs is focused on developing monoclonal and bispecific DR3-blocking antibodies for inflammatory and immune-mediated diseases, aiming for first-in-class therapies.
From a technical perspective, the stock is in a tricky spot. It's still hanging just above its 200-day simple moving average (SMA) of $4.01, which is a positive long-term sign. But it's trading 22.2% below its 20-day SMA of $5.67 and 32% below its 50-day SMA of $6.49, which keeps the intermediate trend pointing down. The fact that the 20-day SMA is below the 50-day SMA adds to that bearish near-term structure, even though the stock is up a whopping 280.17% over the past 12 months.
Momentum is the bigger story right now. The relative strength index (RSI) is at 28.23, which puts the stock in oversold territory. That suggests selling pressure has become stretched. RSI is like a speedometer for recent price moves—readings this low often coincide with "capitulation-style" selling where bounces can start, but it doesn't guarantee a bottom without follow-through.
Key resistance sits at $5.00, a round-number area that also sits below the cluster of short- and medium-term moving averages. That's where rebounds can stall. As of Wednesday's publication, shares were trading up 6.79% at $4.56, according to market data.
